Grace HalimChief Data Officer

Sheet 08 · Speaking & conversations

Bring the research-data claim whose source conditions need to be understood.

01

The row count that changed the research claim

A 45-minute case discussion · Research-data leaders, programme managers and oversight audiences

I would reconstruct the 2011 account in which 2700 laboratory readings from 900 source samples became 2700 independent samples in my presentation. The session would retain three replicate readings per source and Lina Mervathi's challenge to the interpretation. Participants would consider how a correct count can acquire an unsupported scientific meaning when its label changes. The correction would preserve the useful observations while withdrawing the claim I had added to them.

The discussion would keep statistical inference with the responsible experts and avoid declaring the 900 source samples independent for every possible analysis. I would explain why the correction needed to reach earlier users of the statement, not just a later version of a chart. This is a fictional proposed session, with no actual event or external invitation claimed. A genuine adaptation would require authorised research material and appropriate specialist participation. Its purpose would be to make data-leadership accountability concrete without offering a universal analytical rule or exposing participant records.

02

A missing field is not a finding

A 50-minute research-data workshop · Data executives and teams preparing research material for analysis

The workshop would examine the 18000-record registry with 11200 recorded baseline values and 6800 missing entries. Participants would consider the proposal to code the missing portion as normal and the reason I opposed it. The exercise would focus on what the available source actually established, the possible origins of absence and the expert judgement needed for the intended use. It would preserve the practical difficulty that incomplete material created for the team.

I would discuss the S$2.2 million source and fitness review without claiming that every absent value was later recovered. The session would not give clinical advice or prescribe a statistical treatment for another dataset. Scientific, statistical, clinical and permitted-use decisions remain with the relevant owners. This invented format shows a substantive speaking topic for a data leader's site, rather than a record of delivered training. A real version should protect participant information, use approved examples and explain the distinction between a preparation choice and a supported finding.

03

The common unit did not finish the comparability review

A 40-minute lecture with moderated questions · Research-portfolio sponsors, data leaders and scientific programme teams

I would use the 2023 proposal involving 240000 readings from twelve studies to discuss the method context behind a combined view. Nine studies used one measurement method and three another. The session would give Marcus Selvarne's request for a compact portfolio chart a fair hearing, then examine why a shared reported unit did not settle the scientific comparison. Participants would consider the supporting detail the responsible experts needed before the presentation could support a pooled interpretation.

The selected response kept the method families visible and funded review rather than declaring equivalence or permanent incomparability. The discussion would distinguish data organisation from scientific judgement and would claim no treatment, patient or product outcome. This is a fictional proposed talk, not a reported conference appearance or a technical certification. A genuine session should use authorised detail and involve the relevant scientific or statistical expertise. Its value would lie in helping a management audience understand why a convenient chart can still depend on an unresolved evidential question.

04

Replayable work and the conclusion it does not certify

A 45-minute archive-governance discussion · Research-data executives, technology owners and committee members

The proposed discussion begins with sixty-four archived analyses, forty-nine successful replays and fifteen missing dependency versions. Participants would examine what the exercise tested and why a successful run did not independently validate every scientific choice. I would describe the decision to retain the split and fund S$2.9 million remedial work, leaving the eventual resolution of the fifteen cases unclaimed.

The session would ask how an archive account can recognise useful capability while preserving the work and expertise still needed. It would distinguish a file inventory from demonstrated replay and a technical result from scientific assessment. This fictional proposal claims no actual speaking event or operational service. A real adaptation should protect code, data and research material through approved processes and avoid prescribing a universal retention policy. The intended contribution is a clearer discussion of evidence and responsibility, including how a board can ask useful questions without operating the archive or deciding the science itself.

Short speaker biography

Grace Halim is a fictional Singapore-based therapeutics CDO whose career follows research analysis into institutional data leadership. Her proposed discussions examine measurement context, missing observations and replayable analyses. A replicate-reading claim she corrected remains part of the record. The sessions demonstrate a specific data perspective without claiming clinical authority or actual speaking engagements.

Standard speaker biography

Grace Halim is an invented research-data leader at the fictional Seravune Therapeutics in Singapore. Her career began in July 1988 and moved through research-project leadership before an internal data appointment in 2005. She became CDO in March 2020 and leads 105 colleagues through six direct reports. Her cases preserve measurement methods, missing registry values, source-sample relationships and the limits of analysis replay. A bounded retrieval improvement is reported alongside an owned counting error. Her boardroom exposure comes through research-data presentations in an executive capacity; a statutory appointment is absent from the record. These proposed speaking formats claim no real event history, scientific endorsement or clinical service available through the profile.

Extended speaker biography

Grace Halim is a fictional Singapore-based Chief Data Officer whose illustrative career spans thirty-eight years with research records. After a statistics degree in 1988, she joined the invented Nalverin Research as an analyst and later became a project lead. She moved to Seravune Therapeutics in 2005, led research and enterprise data, and became CDO in March 2020.

Her current fictional remit comprises 105 colleagues through six direct reports with S$16.8 million delegated 2026 function expense. Scientific judgement, clinical safety, statistical inference, regulatory decisions, consent, privacy, legal matters and technology operations remain separately accountable. Her proposed talks examine the meaning of a row count, missingness in a research registry, measurement methods behind a combined view and the distinction between replaying an analysis and validating its conclusion.

The narrative includes a replicate-reading description she withdrew and an internal retrieval improvement reported within its measured scope. Executive board presentations are recorded without statutory director service. Every institution, colleague and outcome is invented. The profile offers no clinical or research service and claims no delivered speaking engagements. A genuine speaker biography would need verified experience, approved examples and accurate event history. This demonstration shows how a research-data leader could make a substantive contribution understandable while preserving the authority of the specialists who judge the science.

An invitation

Contact

I would consider a discussion about preserving measurement, source and transformation context across research data. A prospective first-board conversation would require permission, preparation, relationship review and a realistic assessment of time. This fictional profile provides no clinical, statistical or research service. A real introduction should describe the evidence-management question through an approved route, without sending participant records, restricted study material or unpublished scientific findings before the relevant owners have considered the request.

Open to
  • Board appointments
  • Speaking invitations

office@gracehalim.example